Latest Headlines

31. Novotech Releases Comprehensive Report On Oncolytic Virus Therapy 1/30/2025

    Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech and small to mid-size pharma companies to accelerate the development of advanced and novel therapeutics, has released its latest report, Oncolytic Virus Therapy: Global Clinical Trial Landscape 2024. This comprehensive whitepaper analyzes the evolving landscape of oncolytic virus therapies (OVT), providing critical insights into this transformative approach to cancer treatment. 

32. Novotech Releases Report On Current State Of Triple-Negative Breast Cancer Clinical Trials 1/30/2025

    Novotech, the leading global full-service clinical Contract Research Organization (CRO), has released a comprehensive report analyzing the global clinical trial and drug development landscape for Triple-Negative Breast Cancer (TNBC). The report highlights significant advancements in therapeutic strategies, regional clinical trial activity, and evolving biomarkers driving innovative TNBC treatments. 

33. Comparing Eye Exams In Mobile Settings To In-Office Exams 1/29/2025

    2020 On-site, a Boston-based mobile optometry company whose mission is to expand access to high-quality vision care including clinical research, has completed its observational study to assess the quality of subjective refraction, autorefraction, and keratometry measurements in a mobile eye setting.

34. Industry-First Solution Revolutionizes CGT Sterile Processing 1/21/2025

    To provide CGT manufacturers with alternatives to using cumbersome biosafety cabinets or tube welding to maintain sterility, CPC (Colder Products Company) introduces the smallest aseptic connector available, the MicroCNX® Nano Series connector.

35. IDT Biologika Appoints Federico Pollano As New Chief Commercial Officer 1/17/2025

    IDT Biologika, a leading global contract development and manufacturing organization (CDMO) for end-to-end services in the development and production of viral vaccines, gene and immunotherapeutics and filling of sterile injectables, appoints Federico Pollano as Chief Commercial Officer effective March 1, 2025.

36. Registration Opens For INTERPHEX 2025 | April 1-3 In NYC: Learning Lab Conference Schedule, Show Floor Content, And New Features Announced 1/16/2025

    Join thousands of industry professionals at INTERPHEX, the premier pharmaceutical and biotechnology event taking place April 1-3, 2025, at the Javits Center in NYC. Here, attendees gain direct access to the tools they need to effectively accelerate their drug-to-market journey.

37. Avance Clinical Leads As The CRO Of Choice For Early Phase Clinical Trials In Australia – Announced At Biotech Showcase 2025 1/14/2025

    Wake Forest, NC, USA | Adelaide, Australia

    Avance Clinical, a leading full-service global Contract Research Organization (CRO) known for delivering high-quality, agile clinical research services, is proud to announce it is the CRO of choice for Early Phase clinical trials in Australia with more than 52% of market share. Avance Clinical Australia leads in the active Phase I trials, registered on clinical trial registry ANZCTR (as of 17 December 2024). More than 80% of Avance Clinical clients are US biotechs.

    Book a meeting with the Avance Clinical team at Biotech Showcase.

38. Nucleus Biologics Becomes First Custom Cell Culture Media Company To Achieve EXCiPACT Certification For The Manufacture Of Excipient GMP Quality Cell Culture Media, Supplements, And Buffers 1/9/2025

    Nucleus Biologics, a leader in precision cell culture media development, is proud to announce that it has achieved an industry-leading quality milestone. It has received EXCiPACT certification for Pharmaceutical Excipients and Pharmaceutical Auxiliary Materials (PAMs) and ISO 9001 certification from SGS.

39. Astraveus Announces World First End-To-End Production of CAR-T Cells Using Microfluidic Technology 1/9/2025

    Astraveus SAS (“Astraveus” or the “Company”), the Benchtop Cell Factory company, today announces the first ever successful end-to-end production of CAR-T cells within a microfluidic benchtop system. Using its fully automated Lakhesys Benchtop Cell Factory^TM, Astraveus has been able to demonstrate the potential of its unique microfluidic cell therapy processing approach, which has the ability to decrease manufacturing costs and increase throughput by an order of magnitude.

40. CRB Announces Exhibition And Speaker Schedule For Advanced Therapies Week 2025 1/9/2025

    Attending the show? Make sure to meet CRB’s team of cell and gene therapy specialists at Advanced Therapies Week in booth 566. CRB’s subject matter expert, Peter Walters, will be presenting an educational seminar in the session “Developing Future Facilities While Supporting the Advanced Therapies Ecosystem."